JAGX · Jaguar Health, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · JAGX

1Y 3Y 5Y Max

Annual Quarterly

Income Statement

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$11.51M	$11.69M	$173.0K◇	$4.33M	-	$9.38M
Cost of Revenue	$3.77M	$1.96M	$2.04M	$2.02M	$2.33M	$3.28M
Gross Profit	$7.74M	$9.73M	($1.86M)◇	$2.32M	-	$6.11M
R&D	$24.97M	$16.54M	$18.60M	$17.65M	$15.08M	$6.41M
SG&A	$18.64M	$16.33M	$16.59M	$17.87M	$17.10M	$14.39M
Total Operating Expenses	$57.42M	$42.52M	$44.05M	$46.37M	$45.04M	$36.03M
D&A	$1.91M	$1.90M	$2.01M	$1.98M	$1.72M	$1.73M
Operating Income	($45.91M)	($30.83M)	($34.29M)	($34.41M)	($40.71M)	($26.65M)
Interest Expense	$67.0K	$231.0K	$6.38M	$12.72M	$8.42M	$2.79M
Income Tax	$0	$0	$0◇	$0	$0	-
Net Income	($53.58M)	($38.49M)	($41.30M)	($47.45M)	($38.65M)	($33.81M)
EPS - Basic	($803.95)	($4574.15)	($93975.00)	($1899450.00)	($11812500.00)	-
EPS - Diluted	($803.95)	($4574.15)	($93975.00)	($1899450.00)	($11812500.00)	-

Balance Sheet

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Cash & Equivalents	$968.0K	$8.00M	$6.47M	$5.47M	$17.05M	$8.09M
Accounts Receivable	$1.52M	$1.53M	$1.97M	$1.88M	$1.71M	$2.10M
Inventory	$8.60M	$10.35M	$9.19M	$7.02M	$4.90M	$2.78M
Accounts Payable	$8.69M	$5.29M	$4.97M	$5.81M	$4.93M	$4.76M
Current Assets	$20.34M	$32.20M	$27.96M	$22.32M	$28.43M	$17.79M
Total Assets	$38.32M	$53.42M	$50.76M	$47.45M	$53.27M	$42.84M
Current Liabilities	$40.65M	$19.70M	$13.99M	$30.34M	$15.47M	$13.22M
Long-term Debt	-	-	-	-	-	-
Total Liabilities	$57.01M	$44.45M	$45.87M	$48.81M	$41.41M	$25.64M
Stockholders' Equity	($18.69M)	$6.49M	$4.90M	($1.36M)	$10.67M	$17.20M
Retained Earnings	($399.92M)	($346.48M)	($308.25M)	($266.95M)	($219.49M)	($166.90M)

Cash Flow

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Operating Cash Flow	($23.69M)	($29.38M)	($33.24M)	($33.10M)	($34.97M)	($15.28M)
Investing Cash Flow	($41.0K)	($231.0K)	-	($1.68M)	($6.0K)	($7.0K)
Financing Cash Flow	$23.67M	$31.20M	$34.23M	$23.18M	$43.94M	$19.49M
CapEx	-	$16.0K	-	$77.0K	$6.0K	$7.0K
Free Cash Flow	-	($29.40M)	-	($33.18M)	($34.98M)	($15.29M)

Ratios

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Profitability
Gross margin	67.2%	83.3%	-1077.5%	53.4%	-	65.1%
Operating margin	-398.8%	-263.8%	-19821.4%	-793.9%	-	-283.9%
EBITDA margin	-382.2%	-247.5%	-18657.8%	-748.2%	-	-265.5%
Net margin	-465.4%	-329.3%	-23872.8%	-1094.7%	-	-360.2%
Free cash flow margin	-	-251.5%	-	-765.4%	-	-162.9%
FCF / Net income	-	0.76	-	0.70	0.90	0.45
R&D / Revenue	216.9%	141.5%	10749.1%	407.1%	-	68.3%
SG&A / Revenue	162.0%	139.7%	9588.4%	412.2%	-	153.3%
Effective tax rate	-	-	-	-	-	-
Return on assets	-139.8%	-72.0%	-81.4%	-100.0%	-72.6%	-78.9%
Return on equity	286.7%	-592.7%	-843.4%	3499.6%	-362.1%	-196.5%
Return on invested capital	-	-	-	-	-	-
Liquidity
Current ratio	0.50	1.63	2.00	0.74	1.84	1.35
Quick ratio	0.29	1.11	1.34	0.50	1.52	1.14
Cash ratio	0.02	0.41	0.46	0.18	1.10	0.61
Leverage
Debt / Equity	-	-	-	-	-	-
Debt / Assets	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Interest coverage	-685.2x	-133.5x	-5.4x	-2.7x	-4.8x	-9.5x
Equity multiplier	-2.05	8.23	10.37	-34.99	4.99	2.49
Liabilities / Assets	1.49	0.83	0.90	1.03	0.78	0.60
Efficiency
Asset turnover	0.30	0.22	0.00	0.09	-	0.22
Inventory turnover	0.44	0.19	0.22	0.29	0.48	1.18
Days sales outstanding	48d	48d	4150d	158d	-	82d
Days inventory outstanding	832d	1931d	1647d	1270d	767d	310d
Days payable outstanding	840d	987d	891d	1050d	771d	530d
Cash conversion cycle	40d	992d	4905d	378d	-	-138d
Valuation
P / E	-	-	-	-	-	-
P / B	-	40.1x	37344.3x	-	4942111.4x	-
P / S	6.6x	22.3x	1057080.5x	103639.5x	-	-
EV / EBITDA	-	-	-	-	-	-
Growth
Revenue growth (YoY)	-1.5%	6656.6%	-96.0%	-	-	62.5%
Revenue CAGR (3y)	38.5%	-	-73.6%	-9.1%	-	29.1%
Revenue CAGR (5y)	4.2%	15.1%	-47.7%	-0.1%	-	105.1%
Gross profit growth (YoY)	-20.5%	-	-	-	-	211.6%
Operating income growth (YoY)	-48.9%	10.1%	0.4%	15.5%	-52.8%	7.9%
Net income growth (YoY)	-39.2%	6.8%	13.0%	-22.8%	-14.3%	12.3%
EPS growth (YoY)	82.4%	95.1%	95.1%	83.9%	-	-
EPS CAGR (3y)	-	-	-	-	-	-
EPS CAGR (5y)	-	-	-	-	-	-
FCF growth (YoY)	-	-	-	5.1%	-128.8%	-
FCF CAGR (5y)	-	-	-	-	-	-
Book value growth (YoY)	-	32.6%	-	-	-38.0%	61.2%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Business segments

$11.51M total

Human Health Segment$11.16M · 96.9%

Animal Health Segment$353.0K · 3.1%

Product / service

$22.69M total

Product$11.34M · 50.0%

Mytesi$11.00M · 48.5%

License$172.0K · 0.8%

Canalevia$148.0K · 0.7%

Neonorm$35.0K · 0.2%

Stability scores

Altman Z′

FY 2025 · bankruptcy risk

-12.78

Distress

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2025 · 9-point quality

2/9

Weak

✗Net income positive
✗Operating cash flow positive
✗ROA improved YoY
✓Cash flow > net income
-Long-term debt decreased
✗Current ratio improved
✗No share dilution
✗Gross margin improved
✓Asset turnover improved

Peer comparison

Same SIC group: Pharmaceutical Preparations

Company	Revenue (last FY)	Net margin	ROE
LLY	$65.18B	31.7%	77.8%
UTHR	$3.18B	41.9%	18.8%
PFE	$62.58B	12.4%	9.0%
ZTS	$9.47B	28.2%	80.2%
VRTX	$12.00B	32.9%	21.2%

Comparing Jaguar Health against the 5 most active filers in the same SIC group.

Cells marked with a small ◇ are sourced from SEC's bulk Financial Statement Data Sets, which can lose dimensional context (notably Revenue and Operating Income for issuers that report by segment). These cells will be replaced with authoritative values from the Company Facts API as the backfill completes.